The Lynx Group
Cholangiocarcinoma News

International Cholangiocarcinoma Patient Registry Accelerates and Supports CCA Research

September 2022, Vol 3, No 3

The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).

What Is ICPR?

ICPR is a collaborative effort between patients and the global CCA research community. Through ICPR, patients are empowered to participate in unique and urgent research efforts by allowing investigators access to their de-identified health records, which are kept secure and confidential per the Health Insurance Portability and Accountability Act (HIPAA) and European General Data Protection Regulation (GDPR).

The goal of this clinical database is to accelerate and support research; for example, it can provide insights into strategies to facilitate earlier diagnoses of CCA. Such insights can also help to understand the most effective, safe, economical, and clinically relevant treatments for CCA. ICPR also encourages collaboration and communication between patients and their medical teams to review management options, seek second opinions, and coordinate treatment plans with caregivers.

Patients and caregivers can join the database online free of charge. In addition to collecting the medical records of current patients with CCA, ICPR accepts posthumous information on former patients to augment medical research.

“The ICPR allows us to understand the natural history of CCA subtypes and changes in the disease over time. It also allows us to identify disease risk factors and their impact on treatment outcomes, evaluate treatment effectiveness using real-world data, and design better clinical trials to aid in developing new targeted therapies,” said CCF Chief Scientific Officer Reham Abdel-Wahab.

Why Is ICPR Important?

ICPR is the first of its kind and seeks to advance life-extending therapies for CCA. In addition, it may catalyze new and repurposed drug trials, protocols, and medications addressing debilitating treatment side effects and possible end-stage complications. Ultimately, ICPR data are positioned to assist researchers in finding a cure for this rare disease with a poor prognosis.

Of the top 8 deadliest cancers, 7 are rare. Rare cancers have a 5-year survival rate <50%, and the 5-year survival rate for patients with CCA is approximately 20%, as patients face challenges with timely diagnoses, access to biomarker testing, and appropriate treatment options.

Studies of disparities in healthcare experiences among patients with CCA compared with patients with more common cancers are scarce. This fact sends an alarm of urgency for systematic data collection to reshape therapies and management approaches. ICPR may be able to identify these disparities and level the healthcare playing field.

How Does ICPR Impact Patients?

ICPR plays a critical role in ensuring that clinicians are provided reliable and relevant data to design more effective care plans, leading to better patient outcomes.

“Being diagnosed with CCA places me in a very special, select group of individuals in the United States, 1 of approximately 10,000 persons diagnosed each year. We are a special family with the unenviable but unique bond of having a little-known and understood severe form of cancer,” said Fred Neubauer, a stage IV CCA patient since 2019.

He continued, “Now, the Cholangiocarcinoma Foundation and global partners are making our family much larger with the advent of ICPR. Strength in patient numbers, data, and global treatment knowledge offer all of us hope that we may achieve advancements in early disease detection, new life-extending treatment opportunities through global clinical trials, and strategies to improve quality of life.”

Clinicians can share the benefits of ICPR participation with patients by:

  • Contributing and driving research forward
  • Improving diagnosis and early detection
  • Advancing therapies
  • Accessing all medical records and images
  • Sharing medical records to enable patients to get second opinions.

ICPR is only available in English and operates on a platform powered by Invitae Ciitizen.

ACCESS TO ICPR

https://cholangiocarcinoma.org/international-cholangiocarcinoma-patient-registry-icpr/

About Cholangiocarcinoma

Cholangiocarcinoma (koh-LAN-jee-oh-KAR-sih-NOH-muh) is a highly lethal and rare bile duct cancer of the liver with a poor prognosis. With approximately 10,000 cases of cholangiocarcinoma being diagnosed in the United States each year, bile duct cancer is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is minimally effective, emphasizing the urgent need for novel therapies.

About Invitae Ciitizen

Ciitizen, by Invitae, was founded by Anil Sethi in honor of his sister Tania, who died of metastatic breast cancer in 2017. Invitae is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Ciitizen aims to provide patients with their complete health information—including clinical, genomic, and imaging data—and allow them to share it with whomever they want at no charge to them or their families.

Related Items

Think Tank of Multidisciplinary Experts Develop Proposals to Improve Outcomes in Patients with CCA
December 2022, Vol 3, No 4
A group of 29 expert scientists and clinicians from the world’s leading academic institutions developed potentially transformative project proposals while gathered in Las Vegas for a 2-day meeting called Cure Cholangiocarcinoma Think Tank (C2T2).
Clinical Trial Enrollment Challenges for Patients with Cholangiocarcinoma
By Reham Abdel-Wahab, MD, PhD; Samantha Pear
June/July 2022, Vol 3, No 2
There is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.
The Cholangiocarcinoma Foundation’s Patient Advocacy Initiatives
March 2022, Vol 3, No 1
At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. The goal of the CCF’s advocacy group is to provide educational and emotional support for the cholangiocarcinoma (CCA) community of patients and caregivers, and to empower them with the knowledge and guidance needed to self-advocate.
The International Cholangiocarcinoma Research Network: Educational and Research Achievements
By Reham Abdel-Wahab, MD, PhD
December 2021, Vol 2, No 4
In 2015, the Cholangiocarcinoma Foundation (CCF) launched the International Cholangiocarcinoma Research Network (ICRN). This network is a global collaborative of clinicians, researchers, and scientists from leading academic medical centers and research institutions working together to improve the prevention, early detection, treatment, and prognosis of cholangiocarcinoma (CCA).
New ICD-11 Codes for Cholangiocarcinoma
December 2021, Vol 2, No 4
The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangio­carcinoma (CCA).
Navigating Compassionate Use Options for Your Patients with Cholangiocarcinoma
By Melinda Bachini
September/October 2021, Vol 2, No 3
I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA.
A Watershed Moment for the Cholangiocarcinoma Community
By Stacie C. Lindsey
June/July 2021, Vol 2, No 2
In an article published last year in CCA News, I shared the Cholangiocarcinoma Foundation (CCF)’s philosophy on taking risks and leveraging collaboration over competition. The CCF was nearing its 15th anniversary, and the FDA had recently approved pemigatinib (Pemazyre), the first targeted therapy approved for cholangiocarcinoma (CCA).
The Urgent Need to Raise Awareness to Cholangiocarcinoma and Fund Research
By Teresa Delcorso-Ellmann
March 2021, Vol 2, No 1
I first learned of cholangiocarcinoma (CCA) in 2015, when my husband Steve was diagnosed with stage IV inoperable intrahepatic CCA and was given a prognosis of less than a year to live. He defied the prognosis and survived for 40 months, until his death in March 2019. When he was diagnosed, neither one of us had ever heard the word “cholangiocarcinoma” and did not know it was possible to have cancer in the bile duct. We both knew that a diagnosis of other gastrointestinal (GI) cancers, such as pancreatic or colon cancer, could be catastrophic and were stunned to realize that the treatment options and outcomes for patients with CCA were the most dismal of all GI cancers.
Where There Is Hope
By Laura R. Hnat
December 2020, Vol 1, No 3
“You have cancer.” These are the 3 little words that everyone dreads hearing and that doctors wish they never had to utter. Yet according to the American Cancer Society, an estimated 1.8 million people will be diagnosed with cancer in the United States this year, and more than 600,000 people will die of it.
Leading the Way to a Paradigm Shift in Cholangiocarcinoma: The International Cholangiocarcinoma Research Network
By Nilo Azad, MD; Mitesh J. Borad, MD
October 2020, Vol 1, No 2
In the past decade, there has been a sea change in awareness about cholangiocarcinoma (CCA). However, the standard of care has remained unchanged for more than 10 years. This year, the FDA approved a new targeted therapy, pemigatinib, which became a treatment option for approximately 10% to 15% of patients with CCA. The process of drug discovery, as well as changes in the standard of care, are becoming increasingly reliant on collaborative approaches that leverage the expertise and resources of a wide range of partners to strengthen the tools and knowledge that advance the research objectives of all stakeholders.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: